Salvage chemotherapy for metastatic XXXX .

@entity1 @entity632 @entity0 @entity1138 @entity786 @entity6239 @entity7828 @entity701 @entity3 @entity5713 @entity1499 @entity3800 @entity1487
Salvage chemotherapy for metastatic @entity0 includes regimens for hormonal responsive @entity1 and @entity1 refractory to @entity786 , @entity1499 , and @entity1487 (CMF) or @entity1487 , @entity632 , and @entity786 (FAC). For hormone responsive @entity1 , @entity7828 , @entity6239 with @entity701 , and @entity3800 provide second-line therapy and produce objective remissions in 50% of @entity1 . Some @entity1 respond to further hormonal manipulation. When @entity3 becomes refractory, combination chemotherapy is the treatment of choice. For those @entity1 refractory to CMF, salvage therapy should consist of single agents, such as @entity1138 , @entity632 , or @entity5713 , or combinations of drugs not contained in the CMF regimen. As with single-agent therapy in previously untreated @entity1 , remission durations are usually short. Two-drug combinations result in response rates from 30% to 50% and longer duration of remission. For @entity1 refractory to FAC, @entity632 is discontinued after reaching a cumulative dose, and therapy is continued with a CMF-type combination. Thus, both @entity632 and @entity1499 are used, and salvage chemotherapy is based on @entity1138 and @entity5713 . All agents used for salvage therapy of @entity0 may produce toxic effects. Appropriate surveillance and limiting the cumulative dose of drugs reduces the risk of irreversible toxic effects.
